An illustration · invented records · this source is real
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial
Kang IM, Forschmiedt JK, Loch MM, Lew DL, et al. (2026). JAMA Oncology. PubMed 41379459 · DOI 10.1001/jamaoncol.2025.5220 · PubMed record
What kind of source: Prespecified secondary analysis of RxPONDER, patient-reported outcomes. Where it sits in the summary: Still being studied. Back to the summary
What it says, in plain language
This study looked at thinking and memory during treatment. Women who received chemotherapy plus endocrine therapy reported more cognitive problems over three years than women on endocrine therapy alone, in both menopausal groups.
Source access: this note uses the published abstract, linked above. The full article was not available for this review and is not included in the folder.
The exact words we relied on
“CET was determined to have a greater negative association with patient-reported CRCI in both the pre- and postmenopausal participants during the 36-month follow-up.” — PMID:41379459, Abstract, Results
How these quotes were checked
Follow the passage links above to the included paper or public source record.
Abstract only. The quotes above come from the paper’s published abstract as held in the PubMed record. They were checked by exact string match against the PubMed record cached on 2026-09-08. This note is limited to the abstract; the full article was not read.
Limits of this source
Patient-reported questionnaire in a subset of 568 participants. Abstract only.
Review
Reviewed by Sarah Kiselycznyk · September 10, 2026. Review scope and verification method: How we researched this.